DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Follicular Lymphoma Pipeline Report
- DelveInsight’s Follicular Lymphoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Follicular Lymphoma treatment.
- The leading Follicular Lymphoma Companies such as Merck & Co, Genentech, Incyte Corporation, Syndax Pharmaceuticals, Dr Reddy’s Laboratories, Novartis, ADC Therapeutics, Xynomic Pharmaceuticals, Cho Pharma Inc., Janssen, XEME Biopharma Inc., Shanghai Yingli Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Mabworks Biotech Co., Ltd., Archigen Biotech, Hutchison Medipharma Limited, Nordic Nanovector, Xynomic Pharmaceuticals, TG Therapeutics, BeiGene, Allogene Therapeutics, MEI Pharma, Inc., Pfizer, Innovent Biologics (Suzhou) Co. Ltd., Enterome, AstraZeneca, Nanjing Sanhome Pharmaceutical, Co., Ltd., Takeda, Bristol-Myers Squibb, TCR2 Therapeutics, and others are developing potential drug candidates to improve the Follicular Lymphoma treatment scenario.
- Promising Follicular Lymphoma Pipeline Therapies such as DRL_RI (Proposed rituximab biosimilar), MabThera®, GP2013, Rituximab, Venetoclax, Bendamustine, tisagenlecleucel, Loncastuximab Tesirine, Idelalisib, Obinutuzumab, PF-05280586, and others.
- The Follicular Lymphoma Companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular Lymphoma.
Recent Developmental Activities in the Follicular Lymphoma Pipeline Report
- Mosunetuzumab (Anti-CD20 x CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cell. Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format).The drug is currently in phase 3 stage of development for the treatment of Follicular Lymphoma.
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
- Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body’s own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.
- Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BTK is a key component of the B-cell receptor, or BCR, signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies. BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignant white blood cells called B-cells. Zanubrutinib is an orally active inhibitor that covalently binds to BTK, resulting in the irreversible inactivation of the enzyme.
Request a sample and discover the recent breakthroughs happening Follicular Lymphoma pipeline landscape @ Follicular Lymphoma Pipeline Outlook Report
Follicular Lymphoma Overview
Follicular lymphoma (FL) is typically a slow-growing or indolent form of non- Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. Common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. Often, patients with FL have no obvious symptoms of the disease at diagnosis. Follicular lymphoma is usually not considered to be curable, but more of a chronic disease. Patients can live for many years with this form of lymphoma.
Follicular Lymphoma Pipeline Insight Report
In the Follicular lymphoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Follicular Lymphoma Emerging Drugs
- Mosunetuzumab – Genentech
- Tafasitamab – Incyte Corporation
- Pembrolizumab: Merck & Co
- Zanubrutinib – BeiGene
Dive deep into rich insights for Follicular Lymphoma drug in the pipeline, visit @ Follicular Lymphoma Treatment Landscape
Follicular Lymphoma Pipeline Analysis Report
There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genetech.
Scope of the Follicular Lymphoma Pipeline Report
- Coverage: Global
- Follicular Lymphoma Companies- Merck & Co, Genentech, Incyte Corporation, Syndax Pharmaceuticals, Dr Reddy’s Laboratories, Novartis, ADC Therapeutics, Xynomic Pharmaceuticals, Cho Pharma Inc., Janssen, XEME Biopharma Inc., Shanghai Yingli Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Mabworks Biotech Co., Ltd., Archigen Biotech, Hutchison Medipharma Limited, Nordic Nanovector, Xynomic Pharmaceuticals, TG Therapeutics, BeiGene, Allogene Therapeutics, MEI Pharma, Inc., Pfizer, Innovent Biologics (Suzhou) Co. Ltd., Enterome, AstraZeneca, Nanjing Sanhome Pharmaceutical, Co., Ltd., Takeda, Bristol-Myers Squibb, TCR2 Therapeutics, and others are developing potential drug candidates to improve the Follicular Lymphoma treatment scenario.
- Follicular Lymphoma Pipeline Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, GP2013, Rituximab, Venetoclax, Bendamustine, tisagenlecleucel, Loncastuximab Tesirine, Idelalisib, Obinutuzumab, PF-05280586, and others.
- Follicular Lymphoma Pipeline Assessment: Mono, Combination and Mono/Combination.
Table of Content
- Introduction
- Follicular Lymphoma Executive Summary
- Follicular Lymphoma: Overview
- Follicular Lymphoma Pipeline Therapeutics
- Follicular Lymphoma Therapeutic Assessment
- Follicular Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mosunetuzumab – Genentech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Pembrolizumab: Merck &Co.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Drug name: Company name
- Drug profiles in the detailed report….. Preclinical and Discovery Stage Products
- Drug name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Follicular Lymphoma Key Companies
- Follicular Lymphoma Key Products
- Follicular Lymphoma- Unmet Needs
- Follicular Lymphoma- Market Drivers and Barriers
- Follicular Lymphoma- Future Perspectives and Conclusion
- Follicular Lymphoma Analyst Views
- Follicular Lymphoma Key Companies
- Appendix
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Follicular Lymphoma drugs?
- How many Follicular Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Follicular Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
For further information on the Follicular Lymphoma pipeline therapeutics, reach out to Follicular Lymphoma Clinical Trials
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/